TY - JOUR
T1 - Day 100 Natural Killer Cell/CD14+HLA-DRDIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
AU - Porrata, Luis F.
AU - Ansell, Stephen M.
AU - Micallef, Ivana
AU - Johnston, Patrick B.
AU - Villasboas Bisneto, Jose (J.C.)
AU - Paludo, Jonas
AU - Durani, Urshila
AU - Markovic, Svetomir Nenad
N1 - Publisher Copyright:
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - Introduction: The infusion of autograft Natural Killer Cells (NKC)/CD14+HLA-DRDIM ratio is a predictor of survival in lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). This study evaluated if the Day 100 NKC/CD14+HLA-DRDIM ratio still functions as a prognostic immune-biomarker. Methods: This was a retrospective, single-institution, cohort analysis including 107 patients in this study that had clinical assessment at Day 100 post-APBHSCT from our prior phase III trial. We evaluated the prognostic ability of the Day 100 NKC/CD14+HLA-DRDIM ratio to predict overall survival (OS) and progression-free survival (PFS) using Cox regression model for outcome analysis and survival by Kaplan–Meier method. Results: The median follow-up from day 100 was 94.7 months (range 4.83–158.1 months) for the entire cohort. Patients with a Day 100 NKC/CD14+HLA-DRDIM ratio ≥1.67 experienced better OS and PFS versus those with a Day 100 NKC/CD14+HLA-DRDIM ratio <1.67: median OS was not reached versus 49.7 months, the 5-year OS rates were 91% (95% CI, 81%–96%) versus 40% (95% CI, 27%–55%), p <.0001, respectively; and median PFS was not reached versus 23.5 months, the 5-year PFS rates were 66% (95% CI, 55%–81%) versus 21% (95% CI, 15%–40%), p <.0001, respectively. Day 100 NKC/CD14+HLA-DRDIM ratio was an independent predictor for OS and PFS in the multivariate analysis. Conclusions: Day 100 NKC/CD14+HLA-DRDIM ratio is a prognostic immune-biomarker in lymphoma patients post- APBHSCT.
AB - Introduction: The infusion of autograft Natural Killer Cells (NKC)/CD14+HLA-DRDIM ratio is a predictor of survival in lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). This study evaluated if the Day 100 NKC/CD14+HLA-DRDIM ratio still functions as a prognostic immune-biomarker. Methods: This was a retrospective, single-institution, cohort analysis including 107 patients in this study that had clinical assessment at Day 100 post-APBHSCT from our prior phase III trial. We evaluated the prognostic ability of the Day 100 NKC/CD14+HLA-DRDIM ratio to predict overall survival (OS) and progression-free survival (PFS) using Cox regression model for outcome analysis and survival by Kaplan–Meier method. Results: The median follow-up from day 100 was 94.7 months (range 4.83–158.1 months) for the entire cohort. Patients with a Day 100 NKC/CD14+HLA-DRDIM ratio ≥1.67 experienced better OS and PFS versus those with a Day 100 NKC/CD14+HLA-DRDIM ratio <1.67: median OS was not reached versus 49.7 months, the 5-year OS rates were 91% (95% CI, 81%–96%) versus 40% (95% CI, 27%–55%), p <.0001, respectively; and median PFS was not reached versus 23.5 months, the 5-year PFS rates were 66% (95% CI, 55%–81%) versus 21% (95% CI, 15%–40%), p <.0001, respectively. Day 100 NKC/CD14+HLA-DRDIM ratio was an independent predictor for OS and PFS in the multivariate analysis. Conclusions: Day 100 NKC/CD14+HLA-DRDIM ratio is a prognostic immune-biomarker in lymphoma patients post- APBHSCT.
KW - autologous peripheral blood hematopoietic stem cell transplantation
KW - CD14+HLA-DR cells
KW - natural Killer cells
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85178467987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178467987&partnerID=8YFLogxK
U2 - 10.1111/ctr.15211
DO - 10.1111/ctr.15211
M3 - Article
C2 - 38041479
AN - SCOPUS:85178467987
SN - 0902-0063
VL - 38
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 1
M1 - e15211
ER -